Thrombosis, Bleeding, and the Promise of Factor XI(a) Inhibition
- PMID: 38325993
- DOI: 10.1016/j.jacc.2023.12.003
Thrombosis, Bleeding, and the Promise of Factor XI(a) Inhibition
Keywords: asundexian; atrial fibrillation; bleeding; factor XI inhibitor; myocardial infarction; placebo; stroke.
Conflict of interest statement
Funding Support and Author Disclosures Dr Andreotti has received consulting/lecture fees from Amgen, AstraZeneca, Bayer, BMS/Pfizer, Daiichi-Sankyo, and Servier. Dr Montalescot has received research or educational grants to the institution or consulting/lecture fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cell-Prothera, Europa, IRIS-Servier, Novartis, Medtronic, MSD, Pfizer, Quantum Genomics, and Sanofi-Aventis. Dr Massetti has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials.J Am Coll Cardiol. 2024 Feb 13;83(6):669-678. doi: 10.1016/j.jacc.2023.12.004. J Am Coll Cardiol. 2024. PMID: 38325992 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
